Dogwood Therapeutics

Company snapshot

Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and neuropathy. The company is currently pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing SP16, a first-in-class LRP

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dogwood Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Dogwood Therapeutics.

1. Jun 5, 2026 Clinical update

   Halneuron — Phase 2

2. Sep 20, 2016 Patent grant

   Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

3. Sep 1, 2015 Patent grant

   Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

4. Jan 8, 2013 Patent grant

   Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors

5. Oct 23, 2012 Patent grant

   Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

View all clinical trial activity →

• What is Dogwood Therapeutics?

  Dogwood Therapeutics is a pharma organization headquartered in Alpharetta, USA. It trades on NYSE under ticker DWTX. Primary therapeutic focus areas include Chemotherapy Induced Neuropathic Pain. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 7 patent record(s

• Is Dogwood Therapeutics publicly traded?

  Yes. Dogwood Therapeutics is listed with ticker DWTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Dogwood Therapeutics develop or market?

  We link 2 drug profile(s) where Dogwood Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dogwood-therapeutics#company-drugs.

• What are the latest developments for Dogwood Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dogwood Therapeutics focus on?

  Dogwood Therapeutics focuses on Chemotherapy Induced Neuropathic Pain based on our analysis of their pipeline programs and drug development activities.